TriangleAsciminib (NCT06629584)
Asciminib trial for Malignant Solid Tumors (NCT06629584). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with Philadelphia-chromosome-positive or BCR::ABL1-positive chronic-phase chronic myeloid leukemia after one previous kinase-inhibitor treatment. Entry requires specified inadequate-response, resistance or intolerance criteria. A history of the T315I mutation excludes participation.
The idea: asciminib blocks the BCR::ABL1 protein that drives leukemia-cell growth by binding a distinct pocket. Patients take 80 milligrams orally once daily in continuous 28-day cycles for two years. Researchers measure molecular response at twelve months, side effects, symptoms and longer-term disease outcomes.
This phase 2 study plans 40 patients. Ghayas Issa leads MD Anderson’s recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.